Autolus Therapeutics Reports Long-Term Success of Obe-Cel in B-ALL Treatment Study
Autolus Therapeutics PLC has reported promising long-term results from its FELIX study, demonstrating the potential of its Obe-Cel cell therapy to induce durable remission in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
2 minutes to read